tirzepatide hfpef trial An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists In patients with cardiometabolic #HFpEF,

Pickett and colleagues described a process in which pharmacists who work with patients for disease state management would refer the patient to a site medication assistance program coordinator who completes or facilitates the remainder of the paperwork, including procuring prescription(s), pre-filled application for completion by the provider, and if approved, refills of medications and reapplication.[22] Our study did not evaluate the time impact of patient enrollment on pharmacist workload in the clinic, but it is a limiting factor in the patient enrollment capacity without additional resources

After steady weight loss, I was able to enjoy physical activity again and saw improvement in my overall health metrics

Weight loss of 2 to 5 pounds is typical

Additionally, some older weight loss medications with banned substances did carry thrombotic risks, creating lasting skepticism toward newer therapies